WO2014080703A1 - ガレクチン9の改変タンパク質 - Google Patents
ガレクチン9の改変タンパク質 Download PDFInfo
- Publication number
- WO2014080703A1 WO2014080703A1 PCT/JP2013/077514 JP2013077514W WO2014080703A1 WO 2014080703 A1 WO2014080703 A1 WO 2014080703A1 JP 2013077514 W JP2013077514 W JP 2013077514W WO 2014080703 A1 WO2014080703 A1 WO 2014080703A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- galectin
- protein
- seq
- peptide
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a modified protein of galectin-9.
- Wild type galectin 9 has a function of correcting the breakdown of the immune system such as suppression of excessive immune reaction or activation of immunity against cancer through T cell differentiation or homeostasis.
- Wild-type galectin 9 is composed of two sugar chain recognition domains (Carbohydrate Recognition Domain: CRD) and a linked peptide region connecting them.
- CRD Carbohydrate Recognition Domain
- Wild-type galectin-9 which is a recombinant produced using E. coli as a host, acts directly on tumor cells (ie, the activity of inducing tumor cell-cell adhesion and tumor cell apoptosis) and the immune system. It has been suggested that this action induces suppression and regression of cancer metastasis.
- wild type galectin 9 does not act on non-activated lymphocytes and induces apoptosis of activated T cells, particularly CD4 positive T cells that cause hyperimmune reactions. Furthermore, it has been clarified that it has a strong apoptosis-inducing ability for synovial cells involved in joint deformation and the like in rheumatism.
- Such a function of wild type galectin 9 indicates that wild type galectin 9 is useful as a therapeutic agent for various diseases.
- Patent Document 1 no effective solution has been reported for the problems of low solubility and low yield of recombinant protein. Therefore, in order to commercialize a medicine using the excellent function of wild-type galectin 9, it is strongly demanded to provide a modified galectin 9 having excellent solubility and yield.
- an object of the present invention is to provide a modified galectin 9 that retains substantially the same physiological activity as wild-type galectin 9 and is excellent in protease stability and solubility.
- the present invention is a protein or a salt thereof comprising NCRD and CCRD, wherein the NCRD C-terminus and CCRD N-terminus are bound directly or indirectly,
- the NCRD is (N1) a peptide comprising the amino acid sequence represented by SEQ ID NO: 1, (N2) a peptide comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and / or added in the amino acid sequence represented by SEQ ID NO: 1 and having a sugar-binding ability, or (N3) a peptide comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 1 and having a sugar-binding ability,
- the CCRD is: A peptide consisting of an N-terminal region and a C-terminal region and having a sugar-binding ability;
- the N-terminal region is (C-N1) a peptide comprising an amino acid sequence in which 1 to 17 amino acids are deleted in the amino acid sequence represented by
- the nucleic acid of the present invention is characterized by having a base sequence encoding the protein of the present invention.
- the expression vector of the present invention is characterized by having the nucleic acid of the present invention.
- the transformant of the present invention has the nucleic acid of the present invention or the expression vector of the present invention.
- the medicament of the present invention comprises at least one of the protein of the present invention and a salt thereof, the nucleic acid of the present invention, and the expression vector of the present invention.
- the protein of the present invention or a salt thereof is a modified form of wild type galectin 9, and hereinafter referred to as a modified form of galectin 9 of the present invention.
- the modified galectin 9 of the present invention retains the same physiological activity as wild-type galectin 9, and is excellent in protease stability (also referred to as resistance or sensitivity) and solubility. Excellent yield when manufactured as a recombinant protein.
- the modified galectin 9 of the present invention not only retains the physiological activity of wild-type galectin, but also has excellent stability, handleability, and yield during production, and thus is extremely useful as a pharmaceutical raw material. I can say that.
- FIG. 1 is a schematic diagram showing the sequence of stabilized galectin-9.
- FIG. 2 is a photograph showing the results of SDS-PAGE of galectin-9 variant in Example 1 of the present invention.
- FIG. 3 is a graph showing the concentration of a deletion type galectin-9 variant in Example 1 of the present invention.
- FIG. 4 is a graph showing the concentration of a deletion / substitution type galectin-9 variant in Example 1 of the present invention.
- FIG. 5 is a graph showing protease stability in Example 1 of the present invention.
- the galectin 9 variant of the present invention has NCRD and CCRD, and a protein in which the C-terminal of NCRD and the N-terminus of CCRD are bound directly or indirectly or Its salt
- the NCRD is (N1) a peptide comprising the amino acid sequence represented by SEQ ID NO: 1, (N2) a peptide comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and / or added in the amino acid sequence represented by SEQ ID NO: 1 and having a sugar-binding ability, or (N3) a peptide comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 1 and having a sugar-binding ability
- the CCRD is: A peptide consisting of an N-terminal region and a C-terminal region and having a sugar-binding ability; The N-terminal region is (C-N1) a peptide comprising an amino acid sequence in which 1 to 17 amino
- Wild type galectin 9 is a protein having two sugar recognition domains (CRD) as described above.
- the modified galectin 9 of the present invention has substantially the same physiological activity as wild-type galectin 9, and exhibits superior protease stability and solubility compared to wild-type galectin 9. Furthermore, the modified galectin 9 of the present invention exhibits an excellent yield at the time of production as a recombinant protein due to the solubility, for example.
- “substantially the same physiological activity” means, for example, that the physiological activity of the modified galectin 9 is the same type of activity as that of the wild-type galectin 9 or a similar type of activity. means.
- the physiological activity of wild-type galectin 9 is, for example, specific binding activity to a specific sugar chain, cytotoxic activity, apoptosis-inducing activity, anti-inflammatory activity, anti-allergic activity, immunoregulatory activity, physiological activity or biological activity. Etc. Furthermore, in the present invention, “substantially the same physiological activity as wild-type galectin 9” means, for example, a physiological activity related to treatment of a disease and the like. And the meaning of yield is not included.
- the modified galectin 9 of the present invention preferably has substantially the same or higher physiological activity as, for example, wild type galectin 9.
- “Substantially the same physiological activity as wild-type galectin 9” means that the physiological activity substantially the same as that of wild-type galectin 9 is comparable.
- Substantially the same or higher is, for example, about 0.001 to about 100 times, preferably about 0.01 to about 100 times, more preferably about about 100 times the physiological activity of wild-type galectin 9. Examples thereof include 0.1 to about 100 times, more preferably about 0.5 to about 100 times.
- solubility means, for example, solubility in an aqueous medium.
- aqueous medium include various buffers such as water, physiological saline, and phosphate buffer, and mixtures thereof. Is given.
- the NCRD is an N-terminal C-type sugar recognition domain (CRD)
- the CCRD is a C-terminal C-type sugar recognition site (CRD).
- the NCRD is any one of the peptides (N1), (N2) and (N3) as described above.
- the NCRD is a peptide having a sugar binding ability as described above.
- the peptide (N1) is a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1.
- the peptide (N2) is a peptide consisting of an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and / or added in the amino acid sequence (N1).
- the peptide of (N2) is not particularly limited as long as it has a function equivalent to that of the peptide of (N1), and specifically, it only needs to have a sugar binding ability.
- the one or several is, for example, 1 to 45, preferably 1 to 30, more preferably 1 to 15, further preferably 1 to 7, particularly preferably 1, 2, or 3. is there.
- the peptide (N3) is a peptide consisting of an amino acid sequence showing 70% or more identity with the amino acid sequence (N1).
- the peptide of (N3) is not particularly limited as long as it has a function equivalent to that of the peptide of (N1), and specifically, it only needs to have a sugar binding ability.
- the identity is, for example, preferably 75% or more, more preferably 80% or more, still more preferably 85% or more, more preferably 90% or more, and particularly preferably 95% or more, 96% or more, 97% or more. 98% or more and 99% or more.
- the CCRD is a peptide having an N-terminal region and a C-terminal region and having a sugar binding ability.
- the N-terminal region and the C-terminal region are shown below, respectively, and these may have a sugar-binding ability as the CCRD in a linked state.
- the N-terminal region in the CCRD is the peptide of (C-N1), that is, a peptide consisting of an amino acid sequence in which 1 to 17 amino acids are deleted from the amino acid sequence represented by SEQ ID NO: 3.
- C-N1 a peptide consisting of an amino acid sequence in which 1 to 17 amino acids are deleted from the amino acid sequence represented by SEQ ID NO: 3.
- SEQ ID NO: 3 the 10th and 11th amino acids (X) are proline or histidine, and preferably one of them is proline, and XX is, for example, Pro-Pro (PP), Pro-His (PH ) Or His-Pro (HP).
- the 12th and 13th amino acid residues (X) are proline or alanine, and preferably one of them is proline, and XX is, for example, Pro-Pro (PP), Pro-Ala (PA) or Ala-Pro (AP) is preferred.
- the lower limit of the number of amino acid residues to be deleted in the peptide (C-N1) is 1, preferably 6, and more preferably 8, and the upper limit thereof is 17.
- the number is preferably 14, more preferably 13, more preferably 12, and the range is, for example, preferably 6-14, more preferably 8-14 or 9-14. More preferably 8 to 13 or 9 to 13, particularly preferably 10 to 12.
- description of a numerical range also means disclosure of values included in the range.
- a description of 6-14 means disclosure of 6, 7, 8, 9, 10, 11, 12, 13, and 14.
- the amino acid deletion in the peptide (C-N1) may be, for example, either a continuous amino acid deletion or a discontinuous amino acid deletion.
- the deletion is preferably a deletion of consecutive amino acids, and particularly preferably a deletion consecutive from the N-terminal amino acid. Further, in the N-terminal region, both continuous amino acid deletion and discontinuous amino acid deletion may exist.
- the deletion of consecutive amino acids it is preferable that the N-terminal amino acid is first, for example, the aforementioned number of amino acids is deleted. As a specific example, for example, 6 to 14 amino acids are preferable, more preferably 8 amino acids. -14 or 9-14, more preferably 8-13 or 9-13, particularly preferably 10-12.
- a proline residue is preferably conserved.
- at least one amino acid residue selected from the group consisting of the 10th, 11th, 12th, 13th, 15th and 17th is proline. It is preferable.
- at least one of the 10th and 11th amino acid residues is proline as described above.
- at least one of the 12th and 13th amino acid residues is proline as described above, for example, Pro-Pro (PP), Pro-Ala (PA) or Ala-Pro (AP) is preferred.
- peptide (C-N1) examples include the amino acid sequences of SEQ ID NOs: 7 to 20.
- the peptide (C-N1) is not limited to the following amino acid sequences.
- the peptide in the C-terminal region of the CCRD is any one of the peptides (C-C1), (C-C2), and (C-C3).
- the peptide (C-C1) is a peptide consisting of the amino acid sequence represented by SEQ ID NO: 5.
- SEQ ID NO: 5 129aa FITTILGGLYPSKSILLSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGSEERSLPRKMPFVRGQSFSVWILCEAHCLKVAVDGQHLFEYYHRLRNLPTINRLEVGGDIQLTHVQT
- the peptide (C-C2) is a peptide consisting of an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and / or added in the amino acid sequence (C-C1).
- the one or several is, for example, 1 to 39, preferably 1 to 26, more preferably 1 to 13, further preferably 1 to 6, particularly preferably 1, 2 or 3. is there.
- the peptide (C-C3) is a peptide consisting of an amino acid sequence showing 70% or more identity with the amino acid sequence (C-C1).
- the identity is, for example, preferably 75% or more, more preferably 80% or more, still more preferably 85% or more, more preferably 90% or more, and particularly preferably 95% or more, 96% or more, 97% or more. 98% or more and 99% or more.
- CCRD composed of the N-terminal region and the C-terminal region
- CCDR peptide is not limited to the following sequences.
- the NCRD and the CCRD may be a directly bound protein or an indirectly bound protein as described above, and preferably the former.
- the NCRD C-terminal and the CCRD N-terminal may be indirectly bonded via a linker, for example.
- the linker include amino acids and peptides.
- the number of amino acid residues of the peptide is not particularly limited, but is preferably short, for example, 2 to 5, preferably 4 or less, 3 or less, 2 or less, or 1.
- the sequence of the peptide is not particularly limited and can be set arbitrarily.
- Specific examples of the peptides include His-Met (HM), Arg-Ile-Pro (RIP), Asn-Leu (NL), Asp-Phe-Val (DFV), and Gly-Ser-Ala (GSA). And the like, and peptides comprising the above sequences.
- modified galectin 9 of the present invention include peptides consisting of any one of the amino acid sequences of SEQ ID NOs: 35 to 48 shown in Table 3 below.
- the galectin-9 variant of this invention is not restrict
- each amino acid may be substituted with, for example, another amino acid or amino acid analog in the class to which each belongs.
- the class include a class classified by chemical characteristics and / or physical characteristics. Examples of the characteristics include hydrophobicity and hydrophilicity, charge, size, and the like. Specific examples include nonpolar amino acids (hydrophobic amino acids), polar amino acids (neutral amino acids), positively charged amino acids (acidic amino acids). ), Negatively charged amino acids (acidic amino acids) and the like.
- nonpolar amino acids examples include alanine, phenylalanine, leucine, isoleucine, valine, proline, tryptophan, methionine, and the like, and examples of the polar amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
- the positively charged amino acid examples include arginine, lysine, and histidine
- examples of the negatively charged amino acid include aspartic acid and glutamic acid.
- the salt of the protein is not particularly limited, and the above-described protein may be in a salt form.
- amino acid residues may be further modified.
- modification include partial decomposition of amino acid residues, modification to a derivative, bonding of a protecting group, bonding of a sugar chain, and the like. Specific examples include amidation or carboxylation such as a C-terminus. Examples include esterification.
- the method for producing the galectin-9 variant of the present invention is not particularly limited, and for example, it may be produced by a genetic engineering technique or a synthetic technique based on its amino acid sequence.
- the former may be, for example, a cell system using a host or a cell-free protein synthesis system.
- a genetic engineering technique for example, a nucleic acid having a base sequence corresponding to the amino acid sequence, an expression vector having the nucleic acid, and the like can be used.
- the method for producing the galectin-9 variant, the nucleic acid encoding the galectin-9 variant and the expression vector will be described later.
- Nucleic acid, expression vector and transformant (1) Nucleic acid The nucleic acid of the present invention is characterized by having a base sequence encoding the modified galectin 9 of the present invention.
- the modified galectin 9 of the present invention can be produced by using the nucleic acid of the present invention and expressing the protein encoded by the nucleic acid in a host or a cell-free protein synthesis system by, for example, genetic engineering techniques.
- the base sequence of the nucleic acid of the present invention is not particularly limited, and can be designed by replacing with a codon based on the amino acid sequence of the modified galectin 9 of the present invention.
- the nucleic acid of the present invention can be synthesized by, for example, genetic engineering techniques or organic synthetic techniques, and can also be referred to as synthetic DNA such as cDNA or synthetic RNA.
- the nucleic acid of the present invention may be, for example, either a sense strand or an antisense strand, or a hybrid thereof.
- the nucleic acid of the present invention includes, for example, the polynucleotide encoding the NCRD (NCRD polynucleotide) and the polynucleotide encoding the CCRD (CCRD polynucleotide), and the CCRD polynucleotide is located at the 3 ′ end of the NCRD polynucleotide.
- Examples include polynucleotides in which the 5 ′ end of the nucleotide is bound directly or indirectly.
- the NCRD polynucleotide and the CCRD polynucleotide are linked so that the respective reading frames correspond to the amino acids of the NCRD and the CCRD.
- a linker may be provided between the NCRD polynucleotide and the CCRD polynucleotide. In this case, it is preferable to design the linker sequence so that the reading frame of the CCRD polynucleotide does not change.
- the linker is, for example, a polynucleotide.
- the (n1) polynucleotide encoding the peptide (N1) is represented by the base sequence of SEQ ID NO: 2, for example.
- SEQ ID NO: 2 atggccttcagcggttcccaggctccctacctgagtccagctgtccccttttctgggactattcaaggaggtctccaggacggacttcagatcactgtcaatgggaccgttctcagctccagtggaaccaggtttgctgtgaactttcagactggcttcagtggaaatgacattgccttccacttcaaccctcggtttgaagatggagggtacgtggtgtgcaacacgaggcagaacggaagctgggtgtgcaacacgaggcagaacggaagctgggggtgtgcaacac
- the (c-n1) polynucleotide encoding the peptide (C-N1) which is the N-terminal region of the CCRD, has, for example, a set of three consecutive bases in the base sequence of SEQ ID NO: 4.
- the codon is represented by a base sequence from which 1 to 17 sets are deleted.
- the number of codon sets to be deleted and the position of the codon to be deleted correspond to, for example, the number of amino acid residues to be deleted and the position of the amino acid to be deleted described in the peptide (C-N1).
- the underlined base is a sequence encoding the 10th to 13th amino acids in SEQ ID NO: 3, and can be set according to the amino acid.
- SEQ ID NO: 4 actcccgccatcccacctatgatgtacnnnnnnnnnnnnnnntatccgatgcct
- polynucleotide (c-n1) polynucleotide examples include the following base sequences.
- the polynucleotide (c-n1) is not limited to the following sequences.
- the (c-c1) polynucleotide encoding the peptide (C-C1) is represented by the base sequence of SEQ ID NO: 6, for example.
- SEQ ID NO: 6 ttcatcaccaccattctgggagggctgtacccatccaagtccatcctcctgtcaggcactgtcctgcccagtgctcagaggttccacatcaacctgtgctctgggaaccacatcgccttccacctgaacccccgttttgatgagaatgctgtggtccgcaacacccagatcgacaactcctgggggtctgaggagcgaagtctgccccgaaaaatgccttcccgtggccagagcttctcagtgtggatcttgtgtgtgaaaatgccctccgt
- a polynucleotide encoding the CCRD consisting of the N-terminal region and the C-terminal region has a sequence number 6 at the 3 ′ end of the base sequence of each sequence number shown in Table 2 above.
- are base sequences in which the 5 ′ ends of these base sequences are linked SEQ ID NOs: 63 to 76 shown in Table 2).
- the CCRD polynucleotide is not limited to these sequences.
- nucleic acid encoding the galectin-9 variant of the present invention include a polynucleotide comprising any one of the nucleotide sequences of SEQ ID NOs: 77 to 90 shown in Table 3 above.
- the nucleic acid of the present invention is not limited to these examples.
- the nucleic acid may be, for example, a polynucleotide, for example, DNA or RNA.
- RNA include a base sequence in which T is replaced with U in the base sequence of the exemplified DNA.
- DNA include sequences containing deoxyribonucleotides and sequences composed of deoxyribonucleotides.
- RNA include sequences containing ribonucleotides and sequences composed of ribonucleotides.
- the nucleic acid may be, for example, a sequence made of an artificial nucleic acid, or the DNA or RNA may be a sequence further containing an artificial nucleic acid. Examples of the artificial nucleic acid include LNA, PNA, BNA and the like.
- the expression vector of the present invention comprises the nucleic acid of the present invention.
- the galectin-9 variant of the present invention can be produced by introducing the expression vector of the present invention into a host, for example, and expressing the protein encoded by the nucleic acid in the obtained transformant.
- the expression vector of the present invention only needs to functionally contain the nucleic acid of the present invention so that the modified galectin 9 of the present invention can be expressed, and other configurations are not particularly limited.
- the expression vector only needs to express the modified galectin-9 of the present invention by, for example, introduction into a non-human host.
- the non-human host is not particularly limited and can be appropriately selected.
- the non-human host include microorganisms, animal cells, insect cells, plant cells, or cultured cells thereof.
- the microorganism include prokaryotes and eukaryotes.
- the prokaryote include, for example, Escherichia such as Escherichia coli, Bacillus such as Bacillus subtilis, Pseudomonas putida such as Pseudomonas putida, Rhizobium meliloti, etc.
- bacteria of the genus Rhizobium include bacteria of the genus Rhizobium.
- Examples of the eukaryote include yeasts such as Saccharomyces cerevisiae and Schizosaccharomyces pombe.
- Examples of the animal cells include COS cells and CHO cells, and examples of the insect cells include Sf9 cells and Sf21 cells.
- the expression vector can be prepared, for example, by inserting the nucleic acid into a backbone vector (hereinafter also referred to as “basic vector”).
- the type of the basic vector is not particularly limited, and can be appropriately determined according to the type of the host into which the expression vector is introduced.
- examples of the basic vector include pET vector (Merck), pCold vector (Takara Bio), PQE vector (QIAGEN) and the like.
- examples of the basic vector include pYE22m, and a commercially available yeast expression vector such as pYES (Invitrogen) or pESC (Stratagene) is used. You can also.
- the basic vector is preferably a binary vector, and examples thereof include pBI121, pPZP202, pBINPLUS, and pBIN19.
- the expression vector preferably has a regulatory sequence that regulates, for example, nucleic acid expression and protein expression.
- the regulatory sequence include a promoter, terminator, enhancer, polyadenylation signal sequence, origin of replication sequence (ori) and the like.
- the origin of the promoter is not particularly limited, and examples thereof include cytomegalovirus (CMV), rous sarcoma virus (RSV), simian virus-40 (SV-40), muscle ⁇ -actin promoter, herpes simplex virus (HSV) and the like. can give.
- a tissue-specific promoter such as a thymidine kinase promoter, a regulatory promoter such as a growth hormone regulatory promoter, a promoter under the control of the lac operon sequence, an inducible such as a zinc-inducible metallothionein promoter Promoters and the like.
- the arrangement of the regulatory sequences is not particularly limited.
- the regulatory sequence only needs to be arranged so that, for example, nucleic acid expression and protein expression can be functionally regulated, and can be arranged based on a known method.
- the regulatory sequence for example, a sequence provided in advance in the basic vector may be used, the regulatory sequence may be further inserted into the basic vector, and the regulatory sequence provided in the basic vector It may be replaced with the regulatory sequence.
- the expression vector may further include a selection marker coding sequence, for example.
- a selection marker include drug resistance markers, fluorescent protein markers, enzyme markers, cell surface receptor markers, and the like.
- transformant of the present invention is characterized by having the nucleic acid of the present invention or the expression vector of the present invention.
- the transformant of the present invention only needs to functionally contain the nucleic acid of the present invention so that the modified galectin 9 of the present invention can be expressed, and other configurations are not particularly limited.
- the transformant can be obtained, for example, by introducing the nucleic acid of the present invention into a host.
- the host is not particularly limited, and examples thereof include the non-human hosts described above.
- the transformant of the present invention may have, for example, the nucleic acid of the present invention as the expression vector of the present invention. In this case, for example, by introducing the expression vector of the present invention into a host. can get.
- the method for introducing the nucleic acid or the expression vector into the host is not particularly limited, and can be performed by a known method.
- the introduction method can be appropriately set depending on, for example, the type of the host.
- Examples of the introduction method include introduction method using gene gun such as particle gun, calcium phosphate method, polyethylene glycol method, lipofection method using liposome, electroporation method, ultrasonic nucleic acid introduction method, DEAE-dextran method, micro glass tube, etc.
- Examples include a direct injection method using a hydrogel, a hydrodynamic method, a cationic liposome method, a method using an introduction aid, and a method using Agrobacterium.
- Examples of the liposome include lipofectamine and cationic liposome, and examples of the introduction aid include atelocollagen, nanoparticles, and polymers.
- the method for producing a galectin 9 variant of the present invention includes, for example, a step of expressing the nucleic acid of the present invention. According to the production method of the present invention, for example, a modified galectin 9 can be obtained with an excellent yield as compared with the case where wild-type galectin 9 is produced as a recombinant protein.
- the production method of the present invention is characterized in that, by expressing the nucleic acid of the present invention, the nucleic acid is transcribed and translated into a protein encoded by the nucleic acid to synthesize the galectin-9 variant of the present invention, Other processes and conditions are not particularly limited.
- the expression of the nucleic acid of the present invention may be performed, for example, in a cell system using a host or in a cell-free protein synthesis system as described above.
- the modified galectin 9 of the present invention can be synthesized by introducing the nucleic acid of the present invention into a host.
- the host is, for example, as described above, and the introduction of the nucleic acid of the present invention into the host may be the introduction of the expression vector of the present invention.
- the culturing step are not particularly limited and can be appropriately determined according to the type of the host.
- the expressed galectin-9 variant of the present invention may be used as it is after expression, or may be purified.
- the purification method is not particularly limited, and examples thereof include salting out, electrophoresis, and various chromatography.
- the galectin 9 variant of the present invention can be used as a medicine.
- the variant of galectin 9 includes, for example, the activity of wild-type galectin 9, such as cytotoxic activity against malignant tumors, apoptosis inducing activity against malignant tumors, antitumor activity against malignant tumors, activated T cells (for example, CD4-positive T cells) or activated B cells are preserved in apoptosis-inducing activity, immunomodulating activity, anti-inflammatory activity and / or anti-allergic activity.
- the galectin-9 modified body of this invention can mention the pharmaceutical use similar to the wild type galectin 9, for example.
- the medicament of the present invention contains at least one of the galectin-9 variant (protein or salt thereof) of the present invention, the nucleic acid of the present invention, and the expression vector of the present invention, and an immunoregulator (immunosuppressive). Including a meaning of an agent), an antitumor agent, a tumor metastasis inhibitor, an analgesic agent, an anti-inflammatory agent, and an anti-inflammatory agent.
- the medicament of the present invention can be used, for example, for treatment or prevention of a disease, and the treatment may be, for example, any of causal therapy and symptomatic therapy, and disappearance of symptoms, alleviation (improvement) of symptoms, and symptoms Any of inhibition of progression of the above may be used.
- the administration target of the medicament of the present invention is not particularly limited, and examples thereof include humans and non-human animals other than humans.
- non-human animals include mammals such as mice, rats, rabbits, horses, sheep, cows, pigs, dogs and cats, birds such as fish and chickens, helminths, insects, reptiles and amphibians.
- the administration method of the medicament of the present invention is not particularly limited, and can be appropriately determined according to the type of disease.
- the administration method may be, for example, oral administration or parenteral administration, and may be direct administration or indirect administration.
- parenteral administration include topical, transdermal, intravenous, intramuscular, subcutaneous, intradermal and intraperitoneal administration.
- the dose is not particularly limited, and can be appropriately determined depending on the administration subject, the type of disease, the degree of disease, and the like.
- the daily dose is, for example, 5 ⁇ g to 5 mg, preferably 50 ⁇ g to 500 ⁇ g, more preferably 100 ⁇ g to 500 ⁇ g, and further preferably 200 ⁇ g to 250 ⁇ g per kg body weight.
- the number of administrations per day is, for example, 1 to 3 times.
- the administration method may be, for example, either in vivo or ex vivo .
- the nucleic acid of the present invention may be administered to a living body of a patient.
- the tissue or cell is It may be introduced into the patient's living body.
- the dosage is not particularly limited, and can be appropriately determined depending on the administration subject, the type of disease, the degree of the disease, and the like.
- the dose is preferably, for example, an amount that expresses the above-described modified galectin-9 of the present invention.
- the daily dose is, for example, 100 ng to 200 mg, preferably 500 ng to 50 mg, more preferably 1 ⁇ g to 2 mg per human tissue. More preferably, it is 5 ⁇ g to 500 ⁇ g.
- the number of administrations per day is, for example, 1 to 3 times.
- the form of the medicament of the present invention can be appropriately determined according to, for example, the administration method as described above.
- Examples of the form include solution preparations, dispersion preparations, semisolid preparations, granular preparations, molded preparations, and leachable preparations.
- Specific examples include tablets, coated tablets, dragees, pills, troches, hard capsules, soft capsules, microcapsules, implants, powders, powders, granules, fine granules , Injection, liquid, elixir, emulsion, irrigation, syrup, water, emulsion, suspension, liniment, lotion, aerosol, spray, inhalant, spray, ointment, plaster , Patches, pasta, cataplasms, creams, oils, suppositories (eg rectal suppositories), tinctures, skin solutions, eye drops, nasal drops, ear drops, coatings, infusions, injections Liquid preparations, powder preparations for preparing liquid preparations, freeze-dried preparations and gel preparations.
- the medicament of the present invention may contain a pharmaceutically acceptable additive in addition to the galectin-9 variant of the present invention, the nucleic acid of the present invention or the expression vector of the present invention.
- the additive is not particularly limited and can be appropriately selected depending on the form of the medicine, and a known substance in the production of the medicine can be used.
- the additive amount of the additive is not particularly limited as long as it does not inhibit the properties of the galectin-9 variant of the present invention contained as an active ingredient.
- the additive examples include a carrier, an adjuvant, an excipient, an excipient, a diluent, a flavor, a fragrance, a sweetener, a vehicle, an antiseptic, a stabilizer, a binder, a pH adjuster, and a buffer.
- a carrier an adjuvant, an excipient, an excipient, a diluent, a flavor, a fragrance, a sweetener, a vehicle, an antiseptic, a stabilizer, a binder, a pH adjuster, and a buffer.
- Surfactant base, solvent, filler, extender, solubilizer, solubilizer, tonicity agent, emulsifier, suspending agent, dispersant, thickener, gelling agent, curing agent, Absorbers, pressure-sensitive adhesives, elastic agents, plasticizers, disintegrating agents, propellants, preservatives, antioxidants, light-shielding agents, moisturizers, relaxation agents, antistatic agents
- Example 1 As described above, in International Publication No. WO2005 / 093064, stabilized galectin 9 consisting of an amino acid sequence in which the region from the 149th proline to the 177th serine of wild type galectin 9M is deleted is reported.
- the amino acid sequence of the stabilized galectin 9 is shown in FIG. 1 (SEQ ID NO: 91), and the stabilized galectin 9 retains the physiological activity of wild-type galectin 9M, and compared with wild-type galectin 9M.
- FIG. 1 SEQ ID NO: 91
- the stabilized galectin 9 retains the physiological activity of wild-type galectin 9M, and compared with wild-type galectin 9M.
- the galectin-9 variant was a protein comprising an amino acid sequence in which NCRD and CCRD were directly linked.
- the amino acid sequence of NCRD SEQ ID NO: 1
- the amino acid sequence of the C-terminal region of CCRD SEQ ID NO: 5
- the amino acid sequence of SEQ ID NO: 3 17.
- Residue the amino acid sequence in which 4, 6, 8, 9, 10, 11, 12, 12, 13, 16 or 16 amino acid residues have been deleted from the N-terminus did.
- galectin-9 variant was named galectin-9 variant mC4, mC6, mC8, mC9m, mC10, mC11, mC12, mC13, mC14, mC16 depending on the number of deleted amino acids in the N-terminal region of CCRD.
- the amino acid sequence and base sequence of the CCRD N-terminal region and the full-length amino acid sequence and base sequence of the stabilized galectin 9 and each galectin 9 variant are shown below.
- An expression vector for expressing the galectin-9 variant was constructed by the following method.
- the amino acid sequence (SEQ ID NO: 91) of the stabilized galectin 9 (hereinafter also referred to as G9Null) in Example 1 of International Publication No. WO2005 / 093064 is shown in FIG.
- the G9Null coding sequence (SEQ ID NO: 92) was inserted into the cloning site (BamHI site) of pET-11a, and the G9Null expression vector pET-G9Null was prepared by a conventional method. It has been confirmed in International Publication No. WO 2005/093064 that the stabilized galectin 9 has the cell death-inducing activity of wild-type galectin 9 and is significantly superior in protease stability compared to wild-type galectin 9 It is done.
- NCRD polynucleotide (SEQ ID NO: 2) encoding the NCRD peptide (SEQ ID NO: 1) is amplified by PCR using the pET-G9Null as a target sequence and the following primers A1 and A2, and purified by agarose gel electrophoresis did.
- A1 5′-CGTCCTCGTCCTCATATGGCCTTCAGCGGTTCCCAGGCT-3 ′ (SEQ ID NO: 93)
- A2 5′-CTGGAAGCTGATGTAGGACAGCTG-3 ′ (SEQ ID NO: 94)
- CCRD1 to CCRD10, 10 types a polyd encoding CCRD (CCRD1 to CCRD10, 10 types) of each variant Nucleotides were amplified and purified by agarose gel electrophoresis.
- B1 5'-TACATCAGCTTCCAGCCACCTATGATGTACCCCCACCCC-3 '(SEQ ID NO: 95)
- C1 5'-TACATCAGCTTCCAGATGATGTACCCCCACCCCGCCTAT-3 '(SEQ ID NO: 96)
- D1 5′-TACATCAGCTTCCAGTACCCCCACCCCGCCTATCCGATG-3 ′
- E1 5′-TACATCAGCTTCCAGCCCCACCCCGCCTATCCGATGCCT-3 ′
- F1 5'-TACATCAGCTTCCAGCACCCCGCCTATCCGATGCCTTTC-3 '(SEQ ID NO: 99)
- G1 5′-TACATCAGCTTCCAGCCCGCCTATCCGATGCCTTTCATC-3 ′
- H1 5'-TACATCAGCTTCCAGGCCTATCCGATGCCTTTCATCACC-3 '(SEQ ID NO: 100)
- H1 5'-TACATCAGCTTCCAGGCCTATCCGATGC
- NCRD polynucleotide
- CCRD1 to CCRD10 polynucleotides
- primer A1 and the primer A4 described below are used for these mixtures.
- Stage PCR was performed, and the resulting PCR product was purified by agarose gel electrophoresis.
- the purified PCR product was cleaved with restriction enzymes NdeI and BamHI, purified, and then ligated to the pET-11a vector cleaved with the same restriction enzymes, and a clone containing the correct sequence was selected according to a standard method. These clones were used as expression vectors for each galectin-9 variant.
- E. coli The product was introduced into E. coli BL21 (DE3) to prepare a transformant for expressing the recombinant protein, and stored at ⁇ 80 ° C. in the presence of about 15% glycerin.
- galectin 9 variant a protein in which the amino acid in the N-terminal region of the CCRD was further substituted for the galectin 9 variants mC9 to mC12 was designed.
- the following shows the type, amino acid sequence and base sequence of the N-terminal region, and full-length amino acid sequence and base sequence for each galectin-9 variant.
- the underlined portion indicates the amino acid residue substituted for the amino acid sequence of mC9 to mC12.
- An expression vector for expressing the galectin-9 variant was constructed by the following method. First, PCR was performed using the expression vectors of mC9, mC10, mC11 and mC12 as target sequences, respectively, using the primer A1 and the following primers L2 to W2 containing the mutated sequence corresponding to the substituted amino acid sequence. The PCR products were purified by agarose gel electrophoresis (muNCRD1 to muNCRD12, 12 types).
- PCR was performed using the expression vectors of mC9, mC10, mC11 and mC12 as the target sequences, respectively, using the primer A4 and the following primers L1 to W1 containing the mutant sequence corresponding to the substituted amino acid sequence.
- the obtained PCR products were purified by agarose gel electrophoresis (muCCRD1 to muCCRD12, 12 types).
- L1 5′-AGCTTCCAGCACCCGCCCGCCTATCCGATGCCT-3 ′ (SEQ ID NO: 118)
- M1 5′-TTCCAGCACGCCGCCTATCCGATGCCTT-3 ′ (SEQ ID NO: 119)
- N1 5′-CCCGCCTATGCGATGCCTTTCATCACCA-3 ′ (SEQ ID NO: 120)
- O1 5′-TATCCGATGGCTTTCATCACCACCATTC-3 ′ (SEQ ID NO: 121)
- P1 5'-TTCCAGCACGCCGCCTATGCGATGGCTTTCATCACCACCATTC-3 '(SEQ ID NO: 122)
- Q1 5′-CTATCCGCCGCCTTTCATCACCACCATT-3 ′ (SEQ ID NO: 123)
- R1 5′-CCCCGCCCCGCCGATGCCTTTCATCACC-3 ′ (SEQ ID NO: 124)
- S1 5'-CAGCACCCCCTATCCGATGCCTTTCA-3 '
- the former PCR product (muNCRD1 to muNCRD12) and the latter PCR product (muCCRD1 to muCCRD12) are mixed, and the second stage PCR using the primers A1 and A4 is performed on these mixtures.
- the obtained PCR product was purified by agarose gel electrophoresis.
- the purified PCR product was cleaved with restriction enzymes NdeI and BamHI, purified, and then ligated to the pET-11a vector cleaved with the same restriction enzymes, and a clone containing the correct sequence was selected according to a standard method. These clones were used as expression vectors for each galectin-9 variant.
- E. coli The product was introduced into E. coli BL21 (DE3) to prepare a transformant, which was stored at ⁇ 80 ° C. in the presence of about 15% glycerin.
- Galectin 9 variant is expressed by the following method, and a test sample of the recombinant protein immediately after expression ( Yield was measured for a test sample of recombinant protein (also referred to as a sample after 3 months of storage) from which insolubles were removed after storage for 3 months after expression.
- the transformant was added to LB-broth containing 100 ⁇ g / mL ampicillin and cultured at 37 ° C. overnight.
- the flask was shaken and cultured at 37 ° C. until A600 nm reached about 0.7.
- Noside (IPTG) was added and cultured at 20 ° C. overnight (16-20 hours). And the microbial cell was collect
- the collected cells were suspended in 80 mL of extraction buffer per flask.
- the composition of the extraction buffer was 10 mmol / L Tris-HCl (pH 7.5), 0.5 mol / L NaCl, 1 mmol / L dithiothreitol (DTT), 1 mmol / L phenylmethylsulfonyl fluoride (PMSF) and 1% Triton X-100.
- lactose-agarose suspension 50% [v / v] in PBS, 1.5 ml as a gel
- the mixture was stirred at 4 ° C. for 1 hour.
- the lactose-agarose gel was recovered by centrifugation at 2,000 ⁇ g for 5 minutes, and the TBS containing 0.03% 3-[(3-colamidopropyl) dimethylammonio] propanesulfonic acid (CHAPS) was collected. Suspended and packed into a minicolumn.
- the gel was washed with TBS containing 0.03% CHAPS 10 times the amount of the gel, and then the protein was eluted with 3 mL of eluate.
- the composition of the eluate was 20 mmol / L Tris-HCl (pH 7.5), 0.15 mol / L NaCl, and 0.2 mol / L lactose.
- the eluate was dialyzed against PBS, centrifuged at 25,000 ⁇ g for 20 minutes to remove insoluble matters, and the resulting supernatant was sterilized by filtration to obtain a final sample. This is hereinafter referred to as a test sample immediately after preparation.
- test sample immediately after this preparation was further stored at 4 ° C. for 3 months. After storage, the sample was centrifuged at 25,000 ⁇ g for 20 minutes to remove insoluble matter, and the resulting supernatant was sterilized by filtration to obtain a test sample after storage for 3 months. Then, similarly to the test sample immediately after the preparation, the protein concentration was measured based on a conventional method, and the yield of each galectin-9 variant was calculated. This was taken as the yield of recombinant protein after 3 months of storage.
- the expression vector pET-G9Null of the stabilized galectin 9 was used, and protein expression and evaluation were performed in the same manner.
- FIG. 2 shows a photograph of SDS-PAGE.
- lane M is a molecular weight marker
- each lane shows a test sample immediately after preparation of each galectin-9 variant.
- FIG. 2 and FIG. 3 it was confirmed that any of the galectin-9 variants were expressed in E. coli and further highly purified by affinity chromatography using lactose-agarose.
- FIG. 3 shows the concentrations of the deletion-type galectin-9 variant and stabilized galectin-9 prepared in (1-1) above.
- A is the result of the test sample immediately after preparation
- B is the result of the test sample after 3 months of storage.
- the vertical axis represents the concentration ( ⁇ g / ml) of the galectin 9 variant or the stabilized galectin 9 in the sample
- the galectin 9 variant represents the average value of two expression experiments
- the stabilized galectin 9 showed an average value and standard deviation of 12 times.
- the galectin 9 variants mC8, mC9, mC10, mC11, mC12, mC13 and mC14 have a protein concentration higher than that of the stabilized galectin 9 (G9Null). Significantly higher. Among them, mC9, mC10, mC12 and mC14 showed extremely high protein concentrations. Also in the test sample after 3 months of storage, the galectin 9 variants mC10, mC11, mC12, and mC13 had significantly higher protein concentrations than the stabilized galectin 9 (G9Null).
- Stabilized galectin 9 exceeded the maximum solubility in the elution step from the column when the final sample (test sample immediately after preparation) was prepared after expression, and thus some stabilized galectin 9 was insolubilized. . And this insoluble matter was removed by the centrifugation process and filtration process after the said elution process. Therefore, as shown in FIG. 3, the stabilized galectin 9 resulted in a low protein concentration in the test sample as described above. On the other hand, in the galectin-9 variant, insolubilization in the elution step was significantly suppressed as compared with the stabilized galectin-9. Therefore, as shown in FIG. 3, the modified galectin 9 resulted in a significantly higher protein concentration in the test sample than the stabilized galectin 9.
- the concentration of the galectin 9 variant in the test sample is significantly higher than the concentration of the stabilized galectin 9 in the test sample, which means that the solubility of the galectin 9 variant is stabilized galectin 9 Means significantly higher than the solubility of.
- the high concentration of the galectin-9 variant in the test sample means that the galectin-9 variant could be recovered in a high yield.
- the solubilization of the protein is generally used in an aqueous solvent such as a buffer solution. Is done. For this reason, as the solubility of the protein is higher, for example, the loss of the protein in the recovery is prevented, and the handleability is also improved. Since the modified galectin 9 of the present invention has excellent solubility as described above, it can be said that it is superior in the production, purification, formulation and the like of the above-mentioned stabilized galectin 9 having the same physiological activity. .
- FIG. 4 shows the concentrations of the deletion / substitution-type galectin-9 variant prepared in (1-2) and the deletion-type galectin-9 variant prepared in (1-1).
- A is the result of the test sample immediately after preparation
- B is the result of the test sample after 3 months of storage.
- the vertical axis represents the concentration ( ⁇ g / ml) of the galectin-9 variant in the test sample
- the galectin-9 variant shows the average value of two expression experiments
- the stabilized galectin 9 showed the average value and standard deviation of 12 times.
- deletion / substitution type galectin-9 variants mC9-HP, mC10-1P1A1, mC10-1P1A2, mC10-HPAP, mC10-HPPY, mC11- AP and mC11-PP had higher protein concentrations compared to stabilized galectin-9.
- mC10-HPAP, mC10-HPPY and mC11-AP which are deletion / substitution-type variants of galectin 9 have a protein concentration higher than that of stabilized galectin 9. it was high.
- mC10-HPAP, mC10-HPPY, mC11-AP and mC11-PP which are deletion / replacement type galectin-9 variants
- the protein concentration was higher than that of the deletion-type galectin-9 variant.
- mC10-HPPY and mC11-AP which are deletion / substitution-type galectin-9 variants, each have a higher protein concentration than the corresponding galectin-9 variant. It was.
- a deletion / substitution type mC10- in which a proline residue is conserved and a tyrosine residue is substituted with a proline residue compared to the deletion type mC10.
- HPPY increased the protein concentration approximately 3.3-fold.
- the deletion / substitution type mC11-AP in which proline-alanine was substituted with alanine-proline compared to the deletion type mC11 increased the protein concentration by about 2.2 times.
- the N-terminal region of the CCRD preserves the 12th or 15th and 17th proline residues of SEQ ID NO: 3, and further has a substitution for a proline residue, thereby It was found that the solubility could be further improved.
- the number of cells was measured in the same manner using the stabilized galectin 9 (G9Null) instead of the galectin 9 variant.
- the galectin 9 variant and the stabilized galectin 9 were determined to obtain a concentration (LD50) that reduces the number of Jurkat cells by 50%, and each galectin 9 variant when the LD50 of the stabilized galectin 9 was taken as 100%. Relative value (%) was determined as specific activity. The results are shown in Table 7 below.
- the galectin-9 variant had significantly higher cell death-inducing activity against Jurkat cells compared to stabilized galectin-9 (G9Null). From this result, it was found that the modified galectin 9 has sufficient physiological activity of the stabilized galectin 9 and has excellent solubility as described above.
- the galectin 9 variant is dissolved in 100 mmol / L Tris-HCl (pH 8.0) containing 150 mmol / L NaCl and 1 mmol / L CaCl 2 so as to be 0.06 mg / mL, and further protease is mixed. And incubated at 37 ° C.
- elastase trade name: Elastase, manufactured by Elastin Products Company, Inc.
- MMP-3 matrix metalloproteinase-3, trade name: Matrix Metalloproteinase-3, manufactured by Biogenesis
- MMP-3 was subjected to activation treatment (37 ° C., 8 hours) with 20 mmol / L Aminophenyl mercurate before use. Sampling was performed over time in an incubator, and each sample was subjected to SDS-PAGE and stained with Coomassie Brilliant Blue R-250.
- wild type galectin 9 preparation (G9S, amino acid sequence of SEQ ID NO: 131) or stabilized galectin 9 (G9Null) prepared in the above (2) was used in place of the galectin 9 variant.
- FIG. 5 shows a photo of SDS-PAGE.
- A is the result using elastase
- B is the result using MMP-3.
- lane M is a molecular weight marker.
- the wild-type G9S was already confirmed to be degraded at 0.5 hours from the start of the incubation, and was largely degraded at 2 hours.
- mC10-HPPY which is a modified galectin 9
- the modified galectin 9 of the present invention is superior in solubility to the stabilized galectin 9, maintains the physiological activity of the wild type galectin 9, and is superior in protease stability to the wild type galectin. confirmed.
- all the galectin 9 variants have significantly increased solubility (ie, yield) compared to the stabilized galectin 9, and among them, mC10, mC11, mC12, mC10-HPPY, mC10-HPAP and mC11-AP showed more than a 5-fold increase compared to stabilized galectin-9.
- mC10-HPPY could stably exist in PBS up to a concentration of at least 2.5 mg / mL, which was confirmed to be about 7 times the concentration of stabilized galectin-9.
- any of the galectin 9 variants exhibits cell death-inducing activity against Jurkat cells, which is one of the physiological activities of wild-type galectin 9, and among them, mC10, mC11, mC12, mC10-HPPY, mC10-HPAP and mC11-AP showed 2-2.5 fold activity compared to stabilized galectin-9.
- the modified galectin 9 showed significant protease stability than the wild type galectin 9. From these results, it can be said that the modified galectin 9 has excellent properties as a highly productive pharmaceutical raw material, and mC10-HPPY has extremely excellent properties.
- the test sample (the galectin 9 variant) just prepared after filtration sterilization prepared in Example 1 (2) was stored at 4 ° C. for about 1 year (344 days).
- the protein concentrations of the test samples were adjusted to 1.88 mg / mL for mC10-HPPY, 1.16 mg / mL for mC10-HPAP and 1.14 mg / mL for mC11-AP, respectively.
- the test sample after storage was centrifuged at 25,000 ⁇ g for 20 minutes to remove insoluble matters, and the supernatant was recovered. About the said test sample after 1-year preservation
- each well was washed once with an activity measurement buffer solution (20 mmol / L HEPES-NaOH (pH 7.5), Hank's balanced salt solution containing 1 mg / mL bovine serum albumin), and 90 ⁇ L of the activity measurement buffer solution per well.
- 10 ⁇ L of a sample containing the modified galectin 9 was added.
- each galectin of Example 1 (1) was adjusted so that the concentration of the galectin 9 variant in each well was 0.1, 0.25, 0.5, 0.75, 1 ⁇ mol / L.
- Nine variants were prepared by diluting with PBS.
- TNP anti-2,4,6-trinitrophenyl
- TNP mouse monoclonal antibody
- concentration concentration
- IgE IgE
- TNP-labeled bovine serum albumin were added and incubated for 1 hour.
- the cells cultured with 0.1% Triton X-100 are solubilized, and ⁇ -hexosaminidase ( ⁇ -HEX) activity in the recovered medium and cell lysate is obtained. It was measured.
- the total ⁇ -HEX activity in the medium and the cell lysate was defined as total ⁇ -HEX activity, and the ratio (%) of ⁇ -HEX activity in the medium to the total ⁇ -HEX activity was determined. This ratio was used as an index of degranulation. This assay was performed as a set of 3 wells.
- Example 1 As a control, 10 ⁇ L of PBS was used instead of the sample, and as a comparative example, the stabilized galectin 9 (G9Null) of Example 1 was added instead of the modified galectin 9 and the same measurement was performed. It was.
- each galectin-9 variant exhibited degranulation inhibitory activity against RBL-2H3 cells in the same manner as the stabilized galectin 9 (G9Null).
- mC8, mC9, mC10, mC11, mC12, mC13, mC10-HPPY, mC10-HPAP and mC11-AP showed significantly higher degranulation inhibitory activity compared to the stabilized galectin 9 (G9Null). . From these results, it was found that the modified galectin 9 sufficiently maintained the physiological activity of the stabilized galectin 9.
- the galectin-9 variant of the present invention maintained excellent solubility even after long-term storage. Moreover, it was confirmed that the galectin-9 variant of the present invention maintains the physiological activity of wild-type galectin-9. Specifically, as shown in the above (1), none of the modified galectin 9 mutants maintained almost the same solubility even after long-term storage, with almost no change in protein concentration after storage for about 1 year. did.
- any of the galectin 9 variants maintains the degranulation inhibitory activity against RBL-2H3 cells, which is one of the physiological activities of the wild type galectin 9, and among them, mC8, mC9, mC10, mC11, mC12, mC13, mC10-HPPY, mC10-HPAP and mC11-AP showed 1.5 to 2.5-fold activity compared to the stabilized galectin 9. From these results, it can be said that the modified galectin-9 has excellent properties as a highly stable pharmaceutical raw material.
- the modified galectin 9 of the present invention retains the same physiological activity as that of the wild-type galectin 9, is excellent in protease stability and solubility, and is produced as a recombinant protein. Also excellent.
- the modified galectin 9 of the present invention not only retains the physiological activity of wild-type galectin, but also has excellent stability, handleability, and yield during production, and thus is extremely useful as a pharmaceutical raw material. I can say that.
Abstract
Description
前記NCRDは、
(N1)配列番号1で表わされるアミノ酸配列からなるペプチド、
(N2)配列番号1で表わされるアミノ酸配列において、1または数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなり、且つ糖結合能を有するペプチド、または、
(N3)配列番号1で表わされるアミノ酸配列と80%以上の同一性を示すアミノ酸配列からなり、且つ糖結合能を有するペプチド
であり、
前記CCRDは、
N末端領域およびC末端領域からなり、且つ糖結合能を有するペプチドであり、
前記N末端領域は、
(C-N1)配列番号3で表わされるアミノ酸配列において、1~17個のアミノ酸が欠失したアミノ酸配列からなるペプチドであり、
前記C末端領域は、
(C-C1)配列番号5で表わされるアミノ酸配列からなるペプチド、
(C-C2)配列番号5で表わされるアミノ酸配列において、1または数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなるペプチド、または、
(C-C3)配列番号5で表わされるアミノ酸配列と80%以上の同一性を示すアミノ酸配列からなるペプチドである
ことを特徴とする。
本発明のガレクチン9改変体は、前述のように、NCRDとCCRDとを有し、前記NCRDのC末端と前記CCRDのN末端とが、直接的または間接的に結合したタンパク質またはその塩であって、
前記NCRDは、
(N1)配列番号1で表わされるアミノ酸配列からなるペプチド、
(N2)配列番号1で表わされるアミノ酸配列において、1または数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなり、且つ糖結合能を有するペプチド、または、
(N3)配列番号1で表わされるアミノ酸配列と80%以上の同一性を示すアミノ酸配列からなり、且つ糖結合能を有するペプチド
であり、
前記CCRDは、
N末端領域およびC末端領域からなり、且つ糖結合能を有するペプチドであり、
前記N末端領域は、
(C-N1)配列番号3で表わされるアミノ酸配列において、1~17個のアミノ酸が欠失したアミノ酸配列からなるペプチドであり、
前記C末端領域は、
(C-C1)配列番号5で表わされるアミノ酸配列からなるペプチド、
(C-C2)配列番号5で表わされるアミノ酸配列において、1または数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなるペプチド、または、
(C-C3)配列番号5で表わされるアミノ酸配列と80%以上の同一性を示すアミノ酸配列からなるペプチドである
ことを特徴とする。
配列番号1:148aa
MAFSGSQAPYLSPAVPFSGTIQGGLQDGLQITVNGTVLSSSGTRFAVNFQTGFSGNDIAFHFNPRFEDGGYVVCNTRQNGSWGPEERKTHMPFQKGMPFDLCFLVQSSDFKVMVNGILFVQYFHRVPFHRVDTISVNGSVQLSYISFQ
配列番号3:17aa
TPAIPPMMYXXXXYPMP
配列番号5:129aa
FITTILGGLYPSKSILLSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGSEERSLPRKMPFVRGQSFSVWILCEAHCLKVAVDGQHLFEYYHRLRNLPTINRLEVGGDIQLTHVQT
(1)核酸
本発明の核酸は、前記本発明のガレクチン9改変体をコードする塩基配列を有することを特徴とする。本発明の核酸を使用し、例えば、遺伝子工学的手法により、宿主または無細胞タンパク質合成系において、前記核酸がコードするタンパク質を発現させることによって、前記本発明のガレクチン9改変体を製造できる。
配列番号2
atggccttcagcggttcccaggctccctacctgagtccagctgtccccttttctgggactattcaaggaggtctccaggacggacttcagatcactgtcaatgggaccgttctcagctccagtggaaccaggtttgctgtgaactttcagactggcttcagtggaaatgacattgccttccacttcaaccctcggtttgaagatggagggtacgtggtgtgcaacacgaggcagaacggaagctgggggcccgaggagaggaagacacacatgcctttccagaaggggatgccctttgacctctgcttcctggtgcagagctcagatttcaaggtgatggtgaacggtatcctcttcgtgcagtacttccaccgcgtgcccttccaccgtgtggacaccatctccgtcaatggctctgtgcagctgtcctacatcagcttccag
配列番号4
actcccgccatcccacctatgatgtacnnnnnnnnnnnntatccgatgcct
配列番号6
ttcatcaccaccattctgggagggctgtacccatccaagtccatcctcctgtcaggcactgtcctgcccagtgctcagaggttccacatcaacctgtgctctgggaaccacatcgccttccacctgaacccccgttttgatgagaatgctgtggtccgcaacacccagatcgacaactcctgggggtctgaggagcgaagtctgccccgaaaaatgcccttcgtccgtggccagagcttctcagtgtggatcttgtgtgaagctcactgcctcaaggtggccgtggatggtcagcacctgtttgaatactaccatcgcctgaggaacctgcccaccatcaacagactggaagtggggggcgacatccagctgacccatgtgcagacatag
本発明の発現ベクターは、前記本発明の核酸を有することを特徴とする。本発明の発現ベクターは、例えば、宿主に導入し、得られた形質転換体で前記核酸がコードするタンパク質を発現させることによって、前記本発明のガレクチン9改変体を製造できる。本発明の発現ベクターは、前記本発明のガレクチン9改変体を発現可能なように、前記本発明の核酸を機能的に有していればよく、その他の構成は、特に制限されない。
本発明の形質転換体は、前記本発明の核酸または前記本発明の発現ベクターを有することを特徴とする。本発明の形質転換体は、前記本発明のガレクチン9改変体を発現可能なように、前記本発明の核酸を機能的に有していればよく、その他の構成は、特に制限されない。
本発明のガレクチン9改変体の製造方法は、例えば、前記本発明の核酸を発現させる工程を有することを特徴とする。本発明の製造方法によれば、例えば、野生型ガレクチン9を組換えタンパク質として製造する場合と比較して、優れた収率でガレクチン9改変体を得ることができる。
本発明のガレクチン9改変体は、医薬としての用途があげられる。具体的に、前記ガレクチン9改変体は、例えば、野生型ガレクチン9の活性、例えば、悪性腫瘍に対する細胞傷害活性、悪性腫瘍に対するアポトーシス誘導活性、悪性腫瘍に対する抗腫瘍活性、活性化T細胞(例えば、CD4陽性T細胞)または活性化B細胞のアポトーシス誘導活性、免疫調節活性、抗炎症活性および/または抗アレルギー活性等が保存されている。このため、本発明のガレクチン9改変体は、例えば、野生型ガレクチン9と同様の医薬用途があげられる。
前述のように、国際公開第WO2005/093064号において、野生型ガレクチン9Mの149番目のプロリンから177番目のセリンまでの領域を欠失したアミノ酸配列からなる安定化ガレクチン9が報告されている。前記安定化ガレクチン9のアミノ酸配列を、図1に示す(配列番号91)そして、前記安定化ガレクチン9について、野生型ガレクチン9Mの生理活性を保持すること、および、野生型ガレクチン9Mと比較して、優れたプロテアーゼ安定性を有することが証明されている。そこで、前記安定化ガレクチン9を改変したガレクチン9改変体について、溶解性、生理活性およびプロテアーゼ安定性を確認した。
(1-1)欠失型のガレクチン9改変体
ガレクチン9改変体は、NCRDとCCRDとが直接連結したアミノ酸配列からなるタンパク質とした。各改変体の間において、NCRDのアミノ酸配列(配列番号1)およびCCRDのC末端領域のアミノ酸配列(配列番号5)は共通とし、CCRDのN末端領域のみ、配列番号3のアミノ酸配列(17アミノ酸残基)において、N末端から4個、6個、8個、9個、10個、11個、12個、13個、14個または16個のアミノ酸残基を欠失させたアミノ酸配列に設定した。各ガレクチン9改変体は、前記CCRDのN末端領域における欠失アミノ酸の個数に応じて、ガレクチン9改変体mC4、mC6、mC8、mC9m、mC10、mC11、mC12、mC13、mC14、mC16とした。以下に、前記安定化ガレクチン9および各ガレクチン9改変体について、CCRDのN末端領域のアミノ酸配列と塩基配列ならびに全長のアミノ酸配列と塩基配列を示す。
ATGGCCTTCAGCGGTTCCCAGGCTCCCTACCTGAGTCCAGCTGTCCCCTTTTCTGGGACTATTCAAGGAGGTCTCCAGGACGGACTTCAGATCACTGTCAATGGGACCGTTCTCAGCTCCAGTGGAACCAGGTTTGCTGTGAACTTTCAGACTGGCTTCAGTGGAAATGACATTGCCTTCCACTTCAACCCTCGGTTTGAAGATGGAGGGTACGTGGTGTGCAACACGAGGCAGAACGGAAGCTGGGGGCCCGAGGAGAGGAAGACACACATGCCTTTCCAGAAGGGGATGCCCTTTGACCTCTGCTTCCTGGTGCAGAGCTCAGATTTCAAGGTGATGGTGAACGGTATCCTCTTCGTGCAGTACTTCCACCGCGTGCCCTTCCACCGTGTGGACACCATCTCCGTCAATGGCTCTGTGCAGCTGTCCTACATCAGCTTCCAGCATATGACTCCCGCCATCCCACCTATGATGTACCCCCACCCCGCCTATCCGATGCCTTTCATCACCACCATTCTGGGAGGGCTGTACCCATCCAAGTCCATCCTCCTGTCAGGCACTGTCCTGCCCAGTGCTCAGAGGTTCCACATCAACCTGTGCTCTGGGAACCACATCGCCTTCCACCTGAACCCCCGTTTTGATGAGAATGCTGTGGTCCGCAACACCCAGATCGACAACTCCTGGGGGTCTGAGGAGCGAAGTCTGCCCCGAAAAATGCCCTTCGTCCGTGGCCAGAGCTTCTCAGTGTGGATCTTGTGTGAAGCTCACTGCCTCAAGGTGGCCGTGGATGGTCAGCACCTGTTTGAATACTACCATCGCCTGAGGAACCTGCCCACCATCAACAGACTGGAAGTGGGGGGCGACATCCAGCTGACCCATGTGCAGACATAG
A1:5'-CGTCCTCGTCCTCATATGGCCTTCAGCGGTTCCCAGGCT-3'(配列番号93)
A2:5'-CTGGAAGCTGATGTAGGACAGCTG-3'(配列番号94)
B1:5'-TACATCAGCTTCCAGCCACCTATGATGTACCCCCACCCC-3'(配列番号95)
C1:5'-TACATCAGCTTCCAGATGATGTACCCCCACCCCGCCTAT-3'(配列番号96)
D1:5'-TACATCAGCTTCCAGTACCCCCACCCCGCCTATCCGATG-3'(配列番号97)
E1:5'-TACATCAGCTTCCAGCCCCACCCCGCCTATCCGATGCCT-3'(配列番号98)
F1:5'-TACATCAGCTTCCAGCACCCCGCCTATCCGATGCCTTTC-3'(配列番号99)
G1:5'-TACATCAGCTTCCAGCCCGCCTATCCGATGCCTTTCATC-3'(配列番号100)
H1:5'-TACATCAGCTTCCAGGCCTATCCGATGCCTTTCATCACC-3'(配列番号101)
I1:5'-TACATCAGCTTCCAGTATCCGATGCCTTTCATCACCACC-3'(配列番号102)
J1:5'-TACATCAGCTTCCAGCCGATGCCTTTCATCACCACCATT-3'(配列番号103)
K1:5'-TACATCAGCTTCCAGCCTTTCATCACCACCATTCTGGGA-3'(配列番号104)
A4:5'-CGACCGGGATCCCTATGTCTGCACATGGGTCAGCTG-3'(配列番号105)
ガレクチン9改変体として、前記ガレクチン9改変体mC9~mC12について、さらに、前記CCRDのN末端領域のアミノ酸を置換したタンパク質を設計した。以下に、各ガレクチン9改変体について、種類、前記N末端領域のアミノ酸配列および塩基配列、全長のアミノ酸配列および塩基配列を示す。下記配列において、下線部は、mC9~mC12のアミノ酸配列に対して、置換したアミノ酸残基を示す。
L2:5'-ATAGGCGGGCGGGTGCTGGAAGCTGATGTAGGA-3'(配列番号106)
M2:5'-GATAGGCGGCGTGCTGGAAGCTGATGTA-3'(配列番号107)
N2:5'-AAGGCATCGCATAGGCGGGGTGCTGGAA-3'(配列番号108)
O2:5'-TGATGAAAGCCATCGGATAGGCGGGGTG-3'(配列番号109)
P2:5'-TGATGAAAGCCATCGCATAGGCGGCGTGCTGGAAGCTGATG-3'(配列番号110)
Q2:5'-TGAAAGGCGGCGGATAGGGGGGGTGCTG-3'(配列番号111)
R2:5'-GGCATCGGCGGGGCGGGGTGCTGGAAGCT-3'(配列番号112)
S2:5'-TCGGATAGGGGGGGTGCTGGAAGCTGAT-3'(配列番号113)
T2:5'-CGGATAGGGGGCCTGGAAGCTGATGTAGGA-3'(配列番号114)
U2:5'-TCGGATAGGGGGGCTGGAAGCTGATGTA-3'(配列番号115)
V2:5'-TGGTGATGAAAGCCATCGCATAGGCCTGGAAGCTGAT-3'(配列番号116)
W2:5'-AGGCATCGGAGGGGCCTGGAAGCTGATGTA-3'(配列番号117)
L1:5'-AGCTTCCAGCACCCGCCCGCCTATCCGATGCCT-3'(配列番号118)
M1:5'-TTCCAGCACGCCGCCTATCCGATGCCTT-3'(配列番号119)
N1:5'-CCCGCCTATGCGATGCCTTTCATCACCA-3'(配列番号120)
O1:5'-TATCCGATGGCTTTCATCACCACCATTC-3'(配列番号121)
P1:5'-TTCCAGCACGCCGCCTATGCGATGGCTTTCATCACCACCATTC-3'(配列番号122)
Q1:5'-CTATCCGCCGCCTTTCATCACCACCATT-3'(配列番号123)
R1:5'-CCCCGCCCCGCCGATGCCTTTCATCACC-3'(配列番号124)
S1:5'-CAGCACCCCCCCTATCCGATGCCTTTCA-3'(配列番号125)
T1:5'-TTCCAGGCCCCCTATCCGATGCCTTTCA-3'(配列番号126)
U1:5'-CCAGCCCCCCTATCCGATGCCTTTCATC-3'(配列番号127)
V1:5'-TTCCAGGCCTATGCGATGGCTTTCATCACCACCATTC-3'(配列番号128)
W1:5'-TTCCAGGCCCCTCCGATGCCTTTCATCACC-3'(配列番号129)
前記(1)で作製した形質転換体を用いて、以下の方法によりガレクチン9改変体を発現させ、発現直後の組換えタンパク質の被検サンプル(発現直後の標品ともいう)と、発現後3ヶ月保存した後に不溶物を除去した組換えタンパク質の被検サンプル(保存3ヶ月後の標品ともいう)について、収量の測定を行った。
RPMI1640-10%FBS培地中で培養したJurkat細胞を遠心分離により回収し、3x104細胞/90μLの濃度となるように新たな培地に懸濁した。得られた懸濁液を、96ウェルプレートに1ウェルあたり90μL播種した。そして、炭酸ガス培養器中で3時間培養した後、ガレクチン9改変体を含むサンプル10μLを各ウェルに加えた。前記サンプルは、各ウェルにおける前記ガレクチン9改変体の濃度が、0.01、0.03、0.1、0.3、1μmol/Lとなるように、前記(1)の各ガレクチン9改変体をPBSで希釈して調製した。つぎに、24時間培養した後、10μLのWST-8試薬を各ウェルに加えて、さらに3時間培養した。そして、10μLの1.2%SDSを各ウェルに加えて、マイクロプレートリーダーを使用して、各ウェルの450nmおよび620nmにおける吸光度を測定し、450nmおよび620nmにおける吸光度の差を算出した。このアッセイは、3ウェルを一組として行った。また、コントロールとして、前記サンプルに代えて10μlのPBSを添加し、同様の測定を行った。そして、コントロールの算出値を100%として、前記サンプルを添加した場合の算出値について、相対値(%)を求めた。この相対値を、細胞数を示す値とした。
前記(2)で調製したガレクチン9改変体mC10-HPPYについて、ヒト組織中に存在するプロテアーゼに対する安定性を確認した。
前記ガレクチン9改変体について、長期保存による溶解性への影響およびRBL-2H3細胞に対する、ガレクチン9改変体の脱顆粒抑制活性を確認した。
前記ガレクチン9改変体を、4℃で約1年間(344日間)保存した後、この長期保存による溶解性への影響を確認した。
RPMI1640-10%FBS培地中で培養したRBL-2H3細胞をトリプシン処理により回収し、2x104細胞/100μLの濃度となるように新たな培地に懸濁した。得られた懸濁液を、96ウェルプレートに1ウェルあたり100μL播種した後、炭酸ガス培養器中で24時間培養した。
Claims (19)
- NCRDとCCRDとを有し、前記NCRDのC末端と前記CCRDのN末端とが、直接的または間接的に結合したタンパク質またはその塩であって、
前記NCRDは、
(N1)配列番号1で表わされるアミノ酸配列からなるペプチド、
(N2)配列番号1で表わされるアミノ酸配列において、1または数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなり、且つ糖結合能を有するペプチド、または、
(N3)配列番号1で表わされるアミノ酸配列と80%以上の同一性を示すアミノ酸配列からなり、且つ糖結合能を有するペプチド
であり、
前記CCRDは、
N末端領域およびC末端領域からなり、且つ糖結合能を有するペプチドであり、
前記N末端領域は、
(C-N1)配列番号3で表わされるアミノ酸配列において、1~17個のアミノ酸が欠失したアミノ酸配列からなるペプチドであり、
前記C末端領域は、
(C-C1)配列番号5で表わされるアミノ酸配列からなるペプチド、
(C-C2)配列番号5で表わされるアミノ酸配列において、1または数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなるペプチド、または、
(C-C3)配列番号5で表わされるアミノ酸配列と80%以上の同一性を示すアミノ酸配列からなるペプチドである
ことを特徴とするタンパク質またはその塩。 - 前記CCRDの前記N末端領域のアミノ酸の欠失が、連続したアミノ酸の欠失または不連続のアミノ酸の欠失である、請求項1記載のタンパク質またはその塩。
- 前記CCRDの前記N末端領域のアミノ酸の欠失が、連続したアミノ酸の欠失である、請求項1記載のタンパク質またはその塩。
- 前記CCRDの前記N末端領域のアミノ酸の欠失が、N末端のアミノ酸から連続する欠失である、請求項3記載のタンパク質またはその塩。
- 前記CCRDの前記N末端領域において欠失するアミノ酸残基数が、6~14個である、請求項1から4のいずれか一項に記載のタンパク質またはその塩。
- 前記CCRDの前記N末端領域において欠失するアミノ酸残基数が、8~14個である、請求項5記載のタンパク質またはその塩。
- 前記(C-N1)のペプチドにおいて、配列番号3で表わされるアミノ酸配列の10番目、11番目、12番目、13番目、15番目および17番目からなる群から選択された少なくとも一つのアミノ酸残基が、プロリンである、請求項1から6のいずれか一記記載のタンパク質またはその塩。
- 前記(C-N1)のペプチドにおいて、配列番号3で表わされるアミノ酸配列の10番目および11番目のアミノ酸残基が、Pro-Pro、Pro-HisまたはHis-Proである、請求項1から7のいずれか一項に記載のタンパク質またはその塩。
- 前記(C-N1)のペプチドにおいて、配列番号3で表わされるアミノ酸配列の12番目および13番目のアミノ酸残基が、Pro-Pro、Pro-AlaまたはAla-Proである、請求項1から8のいずれか一項に記載のタンパク質またはその塩。
- 前記NCRDとCCRDとが、リンカーを介して間接的に結合しており、
前記リンカーが、アミノ酸またはペプチドである、請求項1から9のいずれか一項に記載のタンパク質またはその塩。 - 前記リンカーがペプチドであり、そのアミノ酸残基数が、2~8個である、請求項10記載のタンパク質またはその塩。
- 前記リンカーが、His-Met、Arg-Ile-Pro、Asn-Leu、Asp-Phe-ValおよびGly-Ser-Alaからなる群から選択された少なくとも一つの配列を含むペプチド、または、前記配列からなるペプチドである、請求項11記載のタンパク質またはその塩。
- 前記CCRDのN末端領域が、配列番号7~20のいずれか一つのアミノ酸配列からなるペプチドである、請求項1から12のいずれか一項に記載のタンパク質またはその塩。
- 前記CCRDが、配列番号21~34のいずれか一つのアミノ酸配列からなるペプチドである、請求項1から13のいずれか一項に記載のタンパク質またはその塩。
- 前記タンパク質が、配列番号35~48のいずれか一つのアミノ酸配列を含むタンパク質である、請求項1から14のいずれか一項に記載のタンパク質またはその塩。
- 請求項1から15のいずれか一項に記載のタンパク質をコードする塩基配列を有することを特徴とする、核酸。
- 請求項16記載の核酸を有することを特徴とする、発現ベクター。
- 請求項16記載の核酸または請求項17記載の発現ベクターを有することを特徴とする、形質転換体。
- 請求項1から15のいずれか一項に記載のタンパク質およびその塩、請求項16記載の核酸、ならびに請求項17記載の発現ベクターの少なくともいずれか一つを含むことを特徴とする、医薬。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014548491A JP5888761B2 (ja) | 2012-11-20 | 2013-10-09 | ガレクチン9の改変タンパク質 |
US14/443,558 US9908921B2 (en) | 2012-11-20 | 2013-10-09 | Modified galectin-9 protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012254349 | 2012-11-20 | ||
JP2012-254349 | 2012-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014080703A1 true WO2014080703A1 (ja) | 2014-05-30 |
Family
ID=50775892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/077514 WO2014080703A1 (ja) | 2012-11-20 | 2013-10-09 | ガレクチン9の改変タンパク質 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9908921B2 (ja) |
JP (1) | JP5888761B2 (ja) |
WO (1) | WO2014080703A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022548279A (ja) * | 2019-11-11 | 2022-11-17 | ジバイオロジックス インコーポレイテッド | 組換え安定化ガレクチン9タンパク質を含む関節リウマチ及び骨疾患予防または治療用薬学的組成物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102267413B1 (ko) | 2019-11-11 | 2021-06-21 | (주)지바이오로직스 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 |
JP2023550415A (ja) * | 2020-11-18 | 2023-12-01 | ジバイオロジックス インコーポレイテッド | 組換え安定化ガレクチン9タンパク質を含む、癌の予防または治療用薬学的組成物 |
KR20240032668A (ko) * | 2022-08-31 | 2024-03-12 | (주)지바이오로직스 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 루푸스 예방 또는 치료용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005093064A1 (ja) * | 2004-03-29 | 2005-10-06 | Galpharma Co., Ltd. | 新規ガレクチン9改変体タンパク質及びその用途 |
-
2013
- 2013-10-09 US US14/443,558 patent/US9908921B2/en active Active
- 2013-10-09 WO PCT/JP2013/077514 patent/WO2014080703A1/ja active Application Filing
- 2013-10-09 JP JP2014548491A patent/JP5888761B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005093064A1 (ja) * | 2004-03-29 | 2005-10-06 | Galpharma Co., Ltd. | 新規ガレクチン9改変体タンパク質及びその用途 |
Non-Patent Citations (6)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022548279A (ja) * | 2019-11-11 | 2022-11-17 | ジバイオロジックス インコーポレイテッド | 組換え安定化ガレクチン9タンパク質を含む関節リウマチ及び骨疾患予防または治療用薬学的組成物 |
JP7468930B2 (ja) | 2019-11-11 | 2024-04-16 | ジバイオロジックス インコーポレイテッド | 組換え安定化ガレクチン9タンパク質を含む関節リウマチ及び骨疾患予防または治療用薬学的組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2014080703A1 (ja) | 2017-01-05 |
JP5888761B2 (ja) | 2016-03-22 |
US20150307574A1 (en) | 2015-10-29 |
US9908921B2 (en) | 2018-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8603967B2 (en) | Carrier peptide fragment and use thereof | |
KR100874947B1 (ko) | 비활성 Wnt 저해 폴리펩티드 및 그 제조방법 | |
JP5888761B2 (ja) | ガレクチン9の改変タンパク質 | |
JPH04502916A (ja) | 精製した毛様体神経栄養因子 | |
EP3808762A1 (en) | Fusion protein bound to cell-permeable peptide, and composition comprising fusion protein or cell-permeable peptide and epithelial cell growth factor as active ingredients | |
US9102755B2 (en) | Highly stabilized epidermal growth factor mutants | |
KR20070096262A (ko) | 세포 도입성 fk506 결합 단백질의 융합 단백질 | |
NZ231997A (en) | Motilin-like polypeptides, their use as pharmaceuticals and production by cyanogen bromide cleavage of fusion proteins | |
JP2011072294A (ja) | 新規抗菌ペプチド | |
EP2480245B1 (en) | A novel method for the production of a antimicrobial peptide | |
KR20040041991A (ko) | 세포내 dna/rna 전달 방법, 및 이것의 기초 및임상학적 응용 | |
JPH07503128A (ja) | ヒト毛様体ニューロン親和性因子の先端欠失型および突然変異タンパク質型の合成と精製 | |
KR20090028624A (ko) | 자가면역질환, 알러지성 질환 및 염증성 질환 치료용 약제 조성물 및 이의 전달 방법 | |
KR102195740B1 (ko) | 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템 | |
AU2019225972A1 (en) | Variants of porcine trypsin | |
JP2012511309A (ja) | Ec−sodのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質 | |
WO2017189826A1 (en) | Use of cell-permeable peptides and non-peptide carriers conjugated with nemo binding domain cargo sequence for the treatment of dry eye disease and uveitis | |
EP1127133A2 (de) | Zellpermeabilität-vermittelndes polypeptid | |
BR112012019992A2 (pt) | conjugados de igf-i poli (etileno glicol) | |
KR102114842B1 (ko) | 세포 투과형 염기성섬유아세포성장인자를 함유하는 피부 생리활성 피부외용제 조성물 | |
KR101254004B1 (ko) | 세포 투과성 설피레독신 융합 단백질을 포함하는 염증 예방 및 치료용 조성물 | |
JP4686780B2 (ja) | 細胞死抑制活性強化タンパク質fnkを用いた脱毛の防止 | |
CN111836826B (zh) | 修饰的egf蛋白,其制备方法及其用途 | |
KR20060017348A (ko) | 세포도입성 보톡신 융합단백질 | |
CN109072217A (zh) | 用于治疗与mcm缺陷相关的病症的甲基丙二酰辅酶a变位酶(mcm)融合构建体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13856575 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014548491 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14443558 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13856575 Country of ref document: EP Kind code of ref document: A1 |